Hôpital Larrey - Academic Profile | RDL Research Database

Publications

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi , Julien Mazières , David Planchard +27 more

2015 The Lancet Oncology 1406 citations

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).

Alexander I. Spira , Keunchil Park , Julien Mazières +7 more

8010 Background: MPDL3280A (anti-PDL1) has demonstrated promising response rates in NSCLC that correlated with PD-L1 expression on tumor-infiltrating immune cells (IC) and/or tu...

2015 Journal of Clinical Oncology 122 citations

IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC.

M. Pérol , Clarisse Audigier-Valette , Olivier Molinier +17 more

9003 Background: Benefit coming from maintenance treatment appears greater for switch maintenance in pts with disease stabilization (SD) while it might be larger for continuatio...

2017 Journal of Clinical Oncology 6 citations

Institution Info

Type: healthcare
Country: FR
Publications: 3
Citations: 1,534

External Links

Identifiers

ROR: https://ror.org/03471w967